Maryland State Retirement & Pension System Has $201,000 Position in Roivant Sciences Ltd. $ROIV

Maryland State Retirement & Pension System decreased its position in Roivant Sciences Ltd. (NASDAQ:ROIV) by 18.9% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 19,881 shares of the company’s stock after selling 4,639 shares during the quarter. Maryland State Retirement & Pension System’s holdings in Roivant Sciences were worth $201,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of ROIV. Bank of New York Mellon Corp grew its stake in Roivant Sciences by 16.3% in the 1st quarter. Bank of New York Mellon Corp now owns 4,000,181 shares of the company’s stock valued at $40,362,000 after buying an additional 560,641 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Roivant Sciences by 83.0% in the first quarter. GAMMA Investing LLC now owns 6,493 shares of the company’s stock worth $66,000 after purchasing an additional 2,945 shares during the period. Russell Investments Group Ltd. lifted its position in shares of Roivant Sciences by 478.6% during the 4th quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company’s stock worth $28,000 after purchasing an additional 1,948 shares during the last quarter. UMB Bank n.a. boosted its stake in Roivant Sciences by 112.7% during the 1st quarter. UMB Bank n.a. now owns 4,143 shares of the company’s stock valued at $42,000 after purchasing an additional 2,195 shares during the period. Finally, LPL Financial LLC grew its holdings in Roivant Sciences by 11.3% in the 4th quarter. LPL Financial LLC now owns 73,308 shares of the company’s stock valued at $867,000 after buying an additional 7,452 shares during the last quarter. 64.76% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Roivant Sciences news, CEO Eric Venker sold 100,000 shares of Roivant Sciences stock in a transaction on Monday, July 21st. The stock was sold at an average price of $11.52, for a total value of $1,152,000.00. Following the completion of the transaction, the chief executive officer owned 1,462,223 shares in the company, valued at approximately $16,844,808.96. The trade was a 6.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Vivek Ramaswamy sold 577,007 shares of the stock in a transaction on Friday, June 20th. The stock was sold at an average price of $11.46, for a total value of $6,612,500.22. Following the sale, the insider owned 37,284,108 shares in the company, valued at $427,275,877.68. The trade was a 1.52% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 3,090,503 shares of company stock worth $34,991,546. 10.80% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ROIV. The Goldman Sachs Group raised Roivant Sciences to a “strong-buy” rating and set a $19.00 price objective for the company in a research report on Thursday, July 10th. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a research note on Wednesday, June 18th. Two analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Roivant Sciences currently has an average rating of “Buy” and a consensus price target of $16.50.

Roivant Sciences Stock Performance

Shares of NASDAQ:ROIV opened at $11.76 on Wednesday. The company has a market capitalization of $7.99 billion, a PE ratio of -16.80 and a beta of 1.15. The company’s fifty day moving average is $11.40 and its 200-day moving average is $10.90. Roivant Sciences Ltd. has a 52 week low of $8.73 and a 52 week high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings data on Thursday, May 29th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.15). The firm had revenue of $7.57 million for the quarter, compared to the consensus estimate of $62.17 million. Roivant Sciences had a negative return on equity of 15.90% and a negative net margin of 2,111.79%.During the same period in the prior year, the company posted ($0.23) earnings per share. On average, analysts forecast that Roivant Sciences Ltd. will post -0.92 EPS for the current year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.